A comparative study of netilmicin-cefoxitin and gentamicin-cefoxitin in surgical patients with serious systemic infection. 1983

M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost

A double-blind, randomized study of gentamicin and netilmicin, each in combination with cefoxitin, was done to compare their respective efficacy and toxicity in patients with serious systemic infection. Thirty-seven surgical patients were evaluated for efficacy and 46 patients were evaluated for toxicity. The most frequently cultured organisms were Escherichia coli (15), Klebsiella sp (9), Proteus sp (6), and Bacteroides sp (4). For 23 patients treated with gentamicin-cefoxitin (G-C), the clinical response was favorable in 20/21 (95.2%) evaluable cases, and elimination or marked reduction of 33/34 (97.1%) organisms was achieved. For 14 patients treated with netilmicin-cefoxitin (N-C), the clinical response was favorable in 13/13 (100%) evaluable cases, and 19/20 (95%) organisms were eliminated or markedly reduced. Nephrotoxicity was defined as an increase in serum creatinine to greater than 25% over baseline with an absolute rise of at least 0.5 mg/100 ml to a value greater than or equal to 1.3 mg/100 ml. Based on these criteria, nephrotoxicity was seen in 2/27 (7.4%) patients treated with G-C and in 3/19 (15.8%) patients treated with N-C. Ototoxicity was defined as a greater than 20 dB loss at any frequency. Based on these criteria, ototoxicity was seen in 5/27 (18.5%) patients treated with G-C and 2/19 (10.5%) patients treated with N-C. The data show no significant difference in toxicity and suggest that netilmicin and gentamicin are both highly effective in combination with cefoxitin in patients who have serious infections after surgery.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009428 Netilmicin Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Certomycin,Netillin,Netilmicin Sulfate,Netrocin,Netromicina,Netromycin,Netromycine,Nétromicine,Sch-20569,Sch 20569,Sch20569
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002440 Cefoxitin A semisynthetic cephamycin antibiotic resistant to beta-lactamase. Cefoxitin Sodium,MK-306,Mefoxin,Mefoxitin,Méfoxin,MK 306,MK306,Sodium, Cefoxitin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004756 Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE. Enterobacterial Infections,Cronobacter Infections,Infections, Enterobacteriaceae,Infections, Enterobacterial,Cronobacter Infection,Enterobacteriaceae Infection,Enterobacterial Infection,Infection, Cronobacter,Infection, Enterobacteriaceae,Infection, Enterobacterial,Infections, Cronobacter
D005260 Female Females

Related Publications

M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
May 1981, The Medical journal of Australia,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
April 1995, Clinical otolaryngology and allied sciences,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
April 1977, Antimicrobial agents and chemotherapy,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
October 1978, Archives of otolaryngology (Chicago, Ill. : 1960),
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
November 1976, Antimicrobial agents and chemotherapy,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
April 1994, The Journal of antimicrobial chemotherapy,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
March 1985, Toxicology and applied pharmacology,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
January 1984, Clinical therapeutics,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
January 1981, The Journal of international medical research,
M P Bubrick, and R J Howard, and S Pancorbo, and R R Lorber, and T W Chin, and R Yost
April 1985, Drug intelligence & clinical pharmacy,
Copied contents to your clipboard!